<DOC>
	<DOCNO>NCT02928406</DOCNO>
	<brief_summary>This multicenter study assess safety atezolizumab second-line treatment participant locally advance metastatic urothelial non-urothelial cancer urinary tract addition evaluate efficacy atezolizumab potential tumor biomarkers associate atezolizumab .</brief_summary>
	<brief_title>A Study Atezolizumab Locally Advanced Metastatic Urothelial Non-Urothelial Carcinoma Urinary Tract</brief_title>
	<detailed_description />
	<mesh_term>Urologic Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participants histologically document locally advanced ( tumor ( T ) 4b , node ( N ) ; T , N 23 ) metastatic ( M1 , Stage IV ) urothelial nonurothelial carcinoma urinary tract Participants measurable nonmeasurable disease accord RECIST v1.1 Must receive one prior combination chemotherapy regimen inoperable , locally advanced metastatic urothelial nonurothelial carcinoma urinary tract Representative formalinfixed paraffinembedded ( FFPE ) tumor specimen block Eastern cooperative oncology group ( ECOG ) performance status 0 , 1 2 Treatment one prior line systemic therapy inoperable , locally advanced metastatic urothelial nonurothelial carcinoma urinary tract Treatment investigational agent participation another clinical trial therapeutic intent within 4 week prior study treatment initiation Evidence significant uncontrolled concomitant disease could affect compliance protocol Significant renal disorder require dialysis indication renal transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>